European Society for Medical Oncology

New data on combination treatments for melanoma

Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according ...

Sep 29, 2014
popularity 0 comments 0

Is Europe putting cancer research at risk?

The European Society for Medical Oncology (ESMO), the leading pan-European association representing medical oncology professionals, has expressed concern that the proposed EU General Data Protection Regulation could make ...

Jul 25, 2014
popularity 0 comments 0